Identification | Back Directory | [Name]
1,4-BenzenediaMine, N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitro- | [CAS]
1421372-67-9 | [Synonyms]
OMT-2 AZD9291 2 EOS-61219 Mutated EGFR-IN-3 AZD9291 intermediate 3 Osimertinib Impurity 34 Osimertinib Intermediate 2 Desacrylamide-Nitro-Osimertinib N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-y N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)- N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-?N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-2-nitro- N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-3-indolyl)-2-pyrimidinyl]-2-nitro-1,4-benzenediamine N-(2-dimethylamino-ethyl)-2-methoxy-n-methyl-n-[4-(1-methyl-1h-indol-3-yl)-pyrimidin-2-yl]-5-nitro-benzene-1,4-diamine N1-(5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)methyl)-2-nitrophenyl)-N1,N2,N2-trimethylethane-1,2-diamine N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-2-nitro-1,4-benzenediamine N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitrobenzene-1,4-diamine 1,4-BenzenediaMine, N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitro- 1,4-BenzenediaMine, N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]-2-nitro-benzene-1,4-diamine | [Molecular Formula]
C25H29N7O3 | [MDL Number]
MFCD28167947 | [MOL File]
1421372-67-9.mol | [Molecular Weight]
475.54 |
Chemical Properties | Back Directory | [Boiling point ]
695.0±65.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [pka]
9.00±0.28(Predicted) |
Hazard Information | Back Directory | [Uses]
Desacrylamide-Nitro-Osimertinib is a derivative of Osimertinib(A808075) a selective EGFR inhibitor, used in the treatments of nonsmall-cell lung cancer (NSCLC). Desacrylamide-Nitro-Osimertinib can be used as a potent EGFRL858R/T790M inhibitor. |
|
|